|
31 Mar 2019 |
Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
|
|
30 Mar 2019 |
Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
|
|
30 Mar 2019 |
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype
|
|
30 Mar 2019 |
Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
|
|
26 Mar 2019 |
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
|
|
26 Mar 2019 |
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia
|
|
21 Mar 2019 |
MolMed received the authorization to start phase I/II clinical investigation with CAR T CD44v6 cells in acute myeloid leukemia and multiple myeloma.
|
|
21 Mar 2019 |
Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials
|
|
20 Mar 2019 |
Trizell Ltd. announces Phase 3 pivotal study of interferon alfa-2b gene therapy in malignant pleural mesothelioma
|
|
19 Mar 2019 |
Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
|
|
14 Mar 2019 |
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
|
|
13 Mar 2019 |
PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment
|
|
11 Mar 2019 |
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
|
|
11 Mar 2019 |
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
|
|
11 Mar 2019 |
Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
|
|
11 Mar 2019 |
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
|
|
07 Mar 2019 |
AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
|
|
07 Mar 2019 |
Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
|
|
06 Mar 2019 |
NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer
|
|
02 Mar 2019 |
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the NMPA
|
|
02 Mar 2019 |
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
|
|
28 Feb 2019 |
Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs
|
|
27 Feb 2019 |
Esperite N.V. (ESP) with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of Bronchopulmonary Dysplasia
|
|
27 Feb 2019 |
Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
|
|
25 Feb 2019 |
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
|
